Podcasts about alder biopharmaceuticals

Bob was born & raised in Dumont, NJ as the youngest of four siblings. He grew up in a typical, middle-class family where his father worked as a policeman and his mother was a stay-at-home mom. Bob worked as a janitor during his time in high school while playing several sports throughout the year.After getting his B.A. in Economics & Religious Studies, he worked as an assistant trader on wall-street for some time before realizing he wanted to do something else. Bob took a job selling pharmaceuticals to doctors for two years before making a significant career move. He then was admitted into the Harvard Business School to pursue an MBA, and he would become one of the top leaders in biotechnology/pharmaceuticals.Throughout his career, Bob made several risky career moves that ended up paying off. At one point, he was managing a $6 billion business at Amgen, a large pharmaceutical corporation, but decided to take a leap of faith and leave to join a smaller company called Juno Therapeutics.In the full podcast, Bob shares career setbacks, temporary failures, and most importantly shares key advice for how you can better prepare yourself to reach your career ambitions.

Dr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer-reviewed scientific publications.

In this episode, we talk to the Henry family who has honored the memory of their loved one lost to migraine disease with the creation of the Danielle Byron Henry Migraine Foundation. The Henrys are committed to instilling hope in people with migraine through their educational and awareness-building programs, including their support of the Headache School and the Shine Her Light events. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Healthcare Direkt är programmet där vi pratar om veckans händelser inom life science. I veckans avsnitt gästas vi av Scandidos vd Görgen Nilsson som berättar om bolagets rapport för det första kvartalet 2019/2020. Vi går igenom trender på strålterapimarknaden och behandlar den årliga ASTRO-kongressen, som är den största globala mässan inom området. ASTRO hölls i år mellan den 15-18 september i Chicago, USA. Elektas kommunikationsdirektör Oskar Bosson delar med sig av sina intryck från ASTRO-mässan. Han tar även upp de områden som Elekta valt att fokusera på under mässan. I nyhetsdelen belyser vi danska Lundbecks förvärv Alder Biopharmaceuticals inom migränmarknaden för nästan 2 miljarder dollar. Cellavisions förvärv av franska RAL Diagnostics omnämns samt Sanionas resultat från en fas 2a-studie med läkemedelskandidaten Tesomet i den sällsynta sjukdomen Prader Willis-syndrom.

In this episode, Dr. Christopher Gottschalk gives a presentation explaining research currently being done at Yale University on the use of psychedelic mushrooms in the treatment of migraine and cluster headache. Additionally, he explains the derivatives and characteristics of drugs currently being used for migraine and cluster treatment and how they compare to psychedelics. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we hear more about the relationship between hormones and migraine over the course of a woman’s life. Neurologist, Dr. Janet Waters discusses migraine and other causes of headaches during pregnancy including medications used and their side effects. Dr. Mary Angela O’Neal continues by discussing the differential diagnosis of secondary headaches in the postpartum period, as well as migraine treatment options during lactation. Lastly, we hear from Dr. Marcie Richardson who explains the role of hormones in migraine during perimenopause and menopause, as well as the use of hormonal contraception to manage migraine in perimenopausal women. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

This extended episode features three lectures on the relationship between hormones and migraine. First, Dr. Julie Roth, a women’s neurologist provides an overview of the differences in migraine manifestation in men vs. women and an explanation on the cause of these differences. In section two, neurologist Dr. Amy Hessler discusses menstrual migraine. She explains the timing of migraine during the menstrual cycle and an assessment of current treatment options for menstrual migraine. Lastly, Dr. Renee Eger, an OB-GYN, summarizes contraceptive options and hormonal management for premenopausal women with migraine including risks and benefits. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, Shoshana Lipson shares anecdotal reports about using CGRP medications for migraine compiled by surveying the 6,000+ member Facebook group CGRP and Migraine Community, which she founded. She details the findings in four areas: Efficacy & expectations, adverse side effects, accessibility and information flow. Most importantly, her studies include a broader range of patients than those permitted in clinical trials, allowing for a potentially more realistic look into the implications and outcomes of using CGRP antagonists. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we hear a brief, yet informative explanation on how best to determine which migraine patients are candidates for Botox by nurse practitioner, Carolyn deBeauport. Additionally, you will hear what patients can expect when using Botox to manage migraine, including side effects, injection placements, associated costs and more. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we share a presentation given by otolaryngologist Dr. Mark Mehle. Despite being geared for the continuing education of other physicians, the content should prove to be very useful for patients to discuss with their own doctors regarding their rhinosinusitis symptoms. Dr. Mehle found that 3 out of 4 of the sinus headache patients referred to him were also positive for migraine. He believes anyone treating rhinosinusitis should be well-versed in migraine care, and that they are 2 parts of the same disease. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Dr. Renee Eger, an OBGYN, summarizes contraceptive options and hormonal management for premenopausal women with migraine including their risks and benefits. This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we share a presentation by Jodie Epstein who spoke at the 2019 Migraine Symposium. Jodie candidly tells her personal story that led her into medical cannabis advocacy. She also shares valuable anecdotal evidence gathered through a survey from her online community, MigraineBuds and findings from three compelling scientific studies.     This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals.    *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we hear a brief lecture by Dr. Mariah Stump, a women’s Internal Medicine doctor and medical acupuncturist. Dr. Stump briefly covers the basics of acupuncture, how it is used and evidence that validates acupuncture as a suitable adjunct therapy for managing migraine.   This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals.    *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we hear from Andrew Cleminshaw and Ashley Hattle-Cleminshaw. They share their individual stories about living with cluster headache, how their disease brought them together and what controversial treatment methods they have used to reduce the frequency and severity of their attacks.   This podcast is sponsored in part by Amgen/Novartis and Alder BioPharmaceuticals.    *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we speak with Lynn Julian, a musician, actress, marathon runner and advocate. Lynn shares her lifelong journey living with an invisible illness from concussions and chronic pain in her early life to traumatic brain injury after the devastating 2013 Boston Marathon bombing. Despite her injuries, perseverance, hard work, and proper diagnosis have led her to advocacy and a purpose through the pain. This podcast is sponsored in part by Amgen/Novartis, Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, we will hear from Dr. Michael Teixido, a neurotologist who specializes in conditions that affect hearing and balance. Dr. Teixido explains the pathophysiology of the different types of migraine, as well as the various symptoms associated with each disorder. Dr. Teixido explains common and rare migraine disorders including familial hemiplegic migraine, migraine with aura, abdominal migraine, precordial migraine and more. This podcast is sponsored in part by Amgen/Novartis, Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

In this episode, Alene Brennan, a nutrition coach, yoga instructor and chef shares natural remedies to help people with migraine reach their optimal health. Alene explains some best practices for incorporating essential oils into a migraine management regimen, including their use for children. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Bob Bratzler, Ph.D. talks about a potential migraine treatment that was actually discovered by chance. Surprisingly, the use of a particular glaucoma medication was bringing headache relief to some patients who had migraine disease as well. This medication contains prostaglandins... The interesting thing is that prostaglandins are usually associated with causing pain, not preventing it... This medication is now undergoing a clinical trial for use as a migraine preventive treatment. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Dr. Shivang Joshi of the Dent Neurologic Institute gives a presentation on the use of Marijuana or Cannabis for treating migraine and cluster diseases.  He touches on a bit of the pharmacology, the history of its use, adverse effects, who uses it, what studies have shown, and legal implications, dosing and more. This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries. *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

Neurologist Dr. Stewart Tepper explains how the new, "designer" CGRP blocking migraine treatments work, how they are delivered and what to expect for efficacy. Dr. Tepper's presentation was recorded in June 2018, after the first of these medications became available to patients in the U.S.   This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.  *The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The Association of Migraine Disorders does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

1) Featured Article: Collateral response modulates the time–penumbra relationship in proximal arterial occlusions2) Lesson of the Week: Migraine and neuromodulationThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 23, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Smriti Agarwal about her paper on collateral circulation in proximal arterial occlusions and extending the scope of thrombolytic therapy. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Stewart Tepper on acute and preventative neuromodulation treatment for migraine. DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell.Dr. Agarwal reports no disclosures.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Tepper is a member of the board for the American Headache Society and has been a consultant for or participated on a paid advisory board for Acorda Therapeutics, Inc; Alder BioPharmaceuticals, Inc; Allergan plc; Amgen, Inc; Avanir Pharmaceuticals, Inc; BioVision, Inc; Charleston Laboratories, Inc; Dr. Reddy’s Laboratories, Ltd; electroCore, LLC; eNeura, Inc; Eli Lilly and Company; GLG Pharma, LLC; Guidepoint Inc, LLC, Ltd; Kimberly-Clark Corporation; Pernix Therapeutics Holdings, Inc; Pfizer, Inc; Scion NeuroStim, LLC; Teva Pharmaceutical Industries, Ltd; and Zosano Pharma, Corp.

Today in FirstWord:

1) Standardized EEG interpretation accurately predicts prognosis after cardiac arrest2) e-Pearl topic: Panayiotopoulos syndrome3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Fugate interviews Dr. Tobias Cronberg about his paper on standardized EEG interpretation and how it predicts prognosis after cardiac arrest. Dr. Sarah Wesley is reading our e-Pearl of the week about Panayiotopoulos syndrome. Dr. Tesha Monteith interviews Dr. Messoud Ashina about the topic of neuroimaging biomarkers and human models for new drug targets: Lessons from PACAP38. DISCLOSURES: Dr. Cronberg receives research support from the Regional Research Support, Region Skane, The Swedish Heart and Lung Association, The Skane University Hospital Foundations, The Gyllenstierna-Krapperup Foundation, The Swedish Society of Medicine, The Koch Foundation and The Segerfalk Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Ashina serves as an associate editor of Cephalgia Member of advisory board: The Journal of Headache and Pain; is a consultant or scientific adviser for the ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received an honoraria for lecturing from Allergan, Inc.; receivesresearch support from the Research Foundation of the Capital Region of Denmark, the Danish Council for Independent Research-Medical Sciences, the Novo Nordisk Foundation, IMK Almene Foundation, and the Cool Sorption Foundation.

Today in FirstWord:

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor.Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.